BidaskClub downgraded shares of Progenics Pharmaceuticals (NASDAQ:PGNX) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday, June 19th.
A number of other equities analysts have also weighed in on PGNX. Cantor Fitzgerald set a $15.00 target price on shares of Progenics Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, March 8th. Zacks Investment Research lowered shares of Progenics Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, March 14th. Finally, ValuEngine upgraded shares of Progenics Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, May 23rd. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $12.44.
Shares of NASDAQ:PGNX traded up $0.09 during trading on Tuesday, reaching $8.22. The stock had a trading volume of 17,782 shares, compared to its average volume of 1,249,664. The firm has a market cap of $625.87 million, a P/E ratio of -9.23 and a beta of 2.60. Progenics Pharmaceuticals has a 52 week low of $4.60 and a 52 week high of $9.12. The company has a debt-to-equity ratio of 0.74, a quick ratio of 6.44 and a current ratio of 6.44.
Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings data on Wednesday, May 9th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. Progenics Pharmaceuticals had a negative net margin of 383.39% and a negative return on equity of 92.43%. The firm had revenue of $3.19 million for the quarter, compared to the consensus estimate of $4.10 million. sell-side analysts anticipate that Progenics Pharmaceuticals will post -0.55 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. boosted its holdings in shares of Progenics Pharmaceuticals by 14.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 247,970 shares of the biotechnology company’s stock valued at $1,476,000 after buying an additional 32,242 shares in the last quarter. Arizona State Retirement System boosted its stake in Progenics Pharmaceuticals by 223.6% in the 4th quarter. Arizona State Retirement System now owns 118,105 shares of the biotechnology company’s stock worth $703,000 after purchasing an additional 81,605 shares in the last quarter. Carillon Tower Advisers Inc. bought a new position in Progenics Pharmaceuticals in the 4th quarter worth about $21,790,000. Landscape Capital Management L.L.C. bought a new position in Progenics Pharmaceuticals in the 4th quarter worth about $514,000. Finally, MetLife Investment Advisors LLC bought a new position in Progenics Pharmaceuticals in the 4th quarter worth about $192,000. Institutional investors and hedge funds own 86.94% of the company’s stock.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.